AbCellera Biologics Inc vs Aecom — how do they compare? AbCellera Biologics Inc trades at $9.14 (market cap $2.99B), while Aecom trades at $67.13 (market cap $8.62B). The key difference: Aecom is far larger — about 2.9× AbCellera Biologics Inc's market cap, and Aecom pays a 1.77% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | ACM | |
|---|---|---|
Market Cap | $2.99B | $8.62B |
Sector | Health | Industrials |
52-Week High | $9.76 | $134.35 |
52-Week Low | $2.78 | $66.86 |
Enterprise Value | $2.58B | $10.81B |
Dividend Yield | — | 1.77% |
Trailing returns across standard periods
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.
Read more on ACM →